Lipoxygenase

CMI977 is a potent inhibitor of 5-Lipoxygenase (5-LO), an enzyme involved in the biosynthesis of leukotrienes. By effectively inhibiting 5-LO, CMI977 demonstrates significant anti-inflammatory properties, making it a valuable tool for research in inflammation and related diseases. Its application extends to studies focused on the modulation of leukotriene-mediated pathways, providing insights into targeted therapies for various inflammatory conditions.

AZD 4407 is a potent inhibitor of 5-lipoxygenase, an enzyme involved in the biosynthesis of leukotrienes. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research in areas such as asthma, arthritis, and other inflammatory diseases. AZD 4407 is utilized to study the modulation of leukotriene-mediated pathways in various biological contexts.

BI-0115 is a selective LOX-1 inhibitor with an IC50 of 5.4 μM, effectively blocking the cellular uptake of oxidized low-density lipoprotein (oxLDL). This compound disrupts receptor activity through the formation of dimers within the homodimeric ligand binding domain. BI-0115 is valuable for research focused on atherosclerosis and cardiovascular diseases, providing insight into the modulation of lipid metabolism and inflammatory processes.

DKI5, or (E)-N’-benzylidenehydrazinecarbothiohydrazide, is a selective inhibitor of LOX-1, with an IC50 value of 22.5 μM. This compound demonstrates potential anti-inflammatory properties by targeting the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). DKI5 is suitable for research applications involving cardiovascular studies and the modulation of atherosclerosis-related pathways.

5-O-Demethylnobiletin is an effective inhibitor of 5-lipoxygenase (5-LOX), exhibiting a potent IC50 of 0.1 μM without impacting COX-2 expression. This polymethoxyflavone, derived from Citrus jambhiri Lush., demonstrates notable anti-inflammatory properties by inhibiting leukotriene B4 (LTB4) production in rat neutrophils and elastase release in human neutrophils with an IC50 value of 0.35 μM. 5-O-Demethylnobiletin is valuable for research applications related to inflammation and leukotriene signaling pathways.

Enofelast (BI-L-239) is a selective inhibitor of 5-lipoxygenase (5-LO) with an IC50 of 2.48 μM, effectively blocking calcium ionophore-induced leukotriene B4 (LTB4) production. Its ability to modulate lipid mediators makes it a valuable tool for studying inflammatory pathways and leukotriene signaling in various biological contexts. Enofelast is suitable for research applications investigating the role of 5-LO in diseases associated with inflammation and immune response.

LY256548 is a potent inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and cyclooxygenase (COX), demonstrating significant anti-ischemic and anti-inflammatory properties. This compound effectively reduces leukotriene B4 production in response to A23187 stimulation. In preclinical models, LY256548 has shown efficacy in mitigating bone damage and paw swelling in rat models of Freund's complete adjuvant-induced arthritis (FCA), making it a valuable tool for research into inflammatory diseases and analgesic mechanisms.

L-652343 is a dual inhibitor of cyclooxygenase and lipoxygenase enzymes. It effectively inhibits the production of leukotriene B4 (LTB4) in isolated human polymorphonuclear leukocytes, demonstrating an IC50 value of 1.4 μM when challenged with Calcimycin. This compound is applicable in the study of inflammatory and immune diseases, providing insights into the mechanisms of these conditions and potential therapeutic interventions.

5-LOX-IN-6 is a potent and selective inhibitor of 5-lipoxygenase (5-LO), exhibiting reversible inhibition. It effectively reduces 5-LO activity in human neutrophils and recombinant human 5-LO with IC50 values of 0.23 µM and 0.086 µM, respectively. By inhibiting leukotriene biosynthesis, 5-LOX-IN-6 serves as a valuable tool in the study of inflammatory and allergic disorders.

E 6080 is a specific inhibitor of 5-lipoxygenase (5-LOX), exhibiting an IC50 of 0.2 μM in rat basophilic leukemia cells. This compound effectively reduces leukotriene release, which is critical in the inflammatory response. E 6080 has demonstrated the ability to inhibit bronchospasm induced by antigen inhalation in sensitized guinea pigs, making it a valuable tool for asthma research and related inflammatory conditions.

A63162 is a selective inhibitor of 5-lipoxygenase (5-LOX), a key enzyme in the biosynthesis of leukotrienes. This compound effectively inhibits both mitogen-induced proliferation of horse mononuclear cells and the synthesis of leukotriene LTB4 in response to Calcimycin at equivalent concentrations. A63162 is useful in research focused on chronic obstructive pulmonary disease, arthritis, and inflammatory bowel disease, offering insights into inflammatory pathways and potential therapeutic interventions.